Beximco Pharmaceuticals (LON:BXP) Reaches New 52-Week High - What's Next?

Key Points

• Beximco Pharmaceuticals Limited reached a new 52-week high price of GBX 43 ($0.57) during trading, indicating a 15.4% increase from its previous closing price of GBX 39 ($0.52).
• The company has a market capitalization of £30.68 billion, a PE ratio of 4.83, and a debt-to-equity ratio of 12.47, reflecting strong financial metrics.
• Beximco Pharma, established in 1976, is a leading manufacturer and exporter of medicines in Bangladesh, transitioning from importing to manufacturing its own products over the decades.

Beximco Pharmaceuticals Limited (LON:BXP - Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as GBX 43 ($0.58) and last traded at GBX 43 ($0.58), with a volume of 126945 shares. The stock had previously closed at GBX 39 ($0.52).

Beximco Pharmaceuticals Stock Performance

The company has a 50 day simple moving average of GBX 38.64 and a 200 day simple moving average of GBX 38.05. The company has a debt-to-equity ratio of 12.47, a quick ratio of 0.37 and a current ratio of 2.13. The company has a market capitalization of £30.33 billion, a PE ratio of 4.77 and a beta of 0.61.

About Beximco Pharmaceuticals

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands.